On Friday, Shares of Amedica Corporation (NASDAQ:AMDA), skyrocketed 37.04% to $0.74.
Amedica Corporation declared that it has signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company.
Under the projected agreement, Amedica will assist this company with their proprietary design, development, manufacture and supply of silicon nitride spinal implants. The two companies will start negotiating the definitive agreement once it is satisfied that all necessary and appropriate regulatory approvals can be obtained without noteworthy expense. The agreement underscores Amedica’s continued focus to provide superior and innovative solutions to the market.
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), declined -2.07% to $144.99, during its last trading session.
BioMarin Pharmaceutical declared an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib (formerly referred to as BMN 673) for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
The company declared that the ABRAZO Phase 2 trial has met the study’s protocol-specified threshold for documented tumor reduction (using the RECIST response rate criteria) in order to warrant expanding enrollment in the study from 70 to 140 patients. The ABRAZO study comprises two cohorts of patients with BRCA mutated metastatic breast cancer. The first cohort comprises of patients who have initially responded to a platinum-containing regimen then progressed, while the second cohort comprises of patients who have received more than two preceding chemotherapy regimens for metastatic disease. The protocol-specified expansion criteria requires that a minimum of five responses per cohort, of up to 35 patients, be observed in order to expand the study. The minimum of 5 responses was seen preceding to full enrollment in each cohort.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
Finally, Sabre Corporation (NASDAQ:SABR), ended its last trade with -0.16% loss, and closed at $25.50.
Sabre Corporation has launched a new portfolio of consortia solutions to assist hotels compete for high value business travelers and connect travel buyers with hotels that cater to business travelers. Sabre will feature the Business Travel Services during the 2015 GBTA Convention at booth #1425.
Many independent and small chain hotels recently find it difficult to compete for new travel agency and corporate business due to limited resources and investments contrast to global hotel chains. Sabre Business Travel Services connects hotels to new business opportunities and assists them compete for and manage corporate accounts. At the same time, the solutions make it easier for travel managers and travel administration companies to identify, negotiate and contract with hotels that best fit their corporate hotel programs.
According to a recent research report sponsored by Sabre and conducted by GBTA, managing supplier relationships and monitoring traveler compliance with corporate travel policies are two of the most time-consuming and important aspects of most corporate travel programs. In addition, as corporate travel managers are more pressed for time and resources, many are asking for expert assistance when building effective hotel programs.
Sabre Corporation provides technology solutions to the travel and tourism industry worldwide. It operates in two segments: Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, counting airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators, with a network of travel buyers comprising online and offline travel agencies, travel administration companies, and corporate travel departments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
